Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1001594 | 1.00 | TDP1 (0.54) | TDP1KMT2AMEN1TSHRLMNA | |
| SCHEMBL1002703 | 1.00 | TDP1 (0.54) | TDP1KMT2AMEN1TSHRLMNA | |
| SCHEMBL1001193 | 0.80 | L3MBTL1 (0.56) | TDP1KMT2AMEN1LMNAL3MBTL1 | |
| SCHEMBL1000432 | 0.78 | KMT2A (0.69) | TDP1KMT2AMEN1TSHRLMNA | |
| SCHEMBL1000551 | 0.76 | LMNA (0.51) | KMT2AMEN1TSHRLMNAHTT | |
| SCHEMBL1001367 | 0.76 | ALDH1A1 (0.58) | KMT2AMEN1LMNAKDM4EALDH1A1 | |
| SCHEMBL1000673 | 0.76 | KMT2A (0.63) | TDP1KMT2AMEN1LMNAHTT | |
| SCHEMBL1003909 | 0.74 | GCK (0.49) | TDP1KMT2AMEN1TSHRLMNA | |
| SCHEMBL1001582 | 0.73 | KMT2A (0.80) | TDP1KMT2AMEN1LMNAL3MBTL1 | |
| SCHEMBL1001546 | 0.73 | TSHR (0.49) | TDP1TSHRLMNAHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020255013-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND CAPSID ASSEMBLY MODULATORS BEING AMIDE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | claimed |
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | claimed |
| EP-2938338-A2 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | Drexel University (US) | 2015-11-04 | — | — | EP | claimed |
| WO-2014106019-A2 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A DREXEL (US) | 2014-07-03 | — | — | WO | claimed |
| WO-2020255013-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND CAPSID ASSEMBLY MODULATORS BEING AMIDE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| US-9938236-B2 | Antiviral agents against HBV infection | DREXEL UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| EP-2938338-A2 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | Drexel University (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2280001-B1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD KK (JP) | 2014-10-15 | — | — | EP | disclosed |
| WO-2014106019-A2 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A DREXEL (US) | 2014-07-03 | — | — | WO | disclosed |
| US-8420823-B2 | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD K.K. (JP) | 2013-04-16 | — | — | US | disclosed |
| EP-2280001-A1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-02-02 | — | — | EP | disclosed |
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD K.K. (JP) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | ELOVL1, ELOVL6, ELOVL3 | TDP1 2513/4885KMT2A 473/4885MEN1 4600/4885 |
| US-20160024004-A1 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | HAVCR2, EIF2AK2, NR1H4 | TDP1 3501/4885KMT2A 3874/4885MEN1 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.